Teoxane SA 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-30 09:01 am Unchanged | 2025-01-30 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing |
| 2025-01-06 09:00 am Unchanged | 2025-01-06 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing |
| 2024-12-19 09:00 am Unchanged | 2024-12-19 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 6.200% | 0 (Unchanged) | Filing |
| 2023-10-24 4:05 pm Purchase | 2023-10-17 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 6,550,800 7.400% | 2,105,000 (+47.35%) | Filing |
| 2023-09-01 09:12 am Purchase | 2023-08-22 | 13D | Revance Therapeutics, Inc. RVNC | Teoxane SA | 4,445,800 5.000% | 4,445,800 (New Position) | Filing |